Feedback PLC Directorate Change (2300V)

TIDMFDBK

RNS Number : 2300V

Feedback PLC

20 July 2018

20 July 2018

Feedback plc

Directorate Change - Chief Executive Officer

Feedback plc (AIM: FDBK, 'Feedback' or the 'Company'), the specialist medical imaging technology company, announces that David Crabb is stepping down as Chief Executive Officer in order to devote more time to his other business interests. He will leave the Company with immediate effect.

During his tenure, David has simplified the Company's structure and directed resources to deliver more effective products and services to its current customer base. This places it in a stronger position to grow organically as it pursues strategic partnerships with larger companies within the pharmaceutical industry.

The Company has initiated a search for a new Chief Executive Officer to take Feedback through its next phase of growth. In the meantime, Dr Alastair Riddell will assume the role of Executive Chairman. A further announcement will be made in due course.

Dr. Riddell said: "On behalf of the Board I would like to acknowledge and thank David for his contribution to Feedback. We wish him well with his future endeavours."

David Crabb said: "It has been a pleasure to contribute to the direction of the Company and I wish the team the best for the future."

For further information, please contact:

 
 Feedback plc                                  [phone] 
  Alastair Riddell, Executive Chairman          [e-mail] 
 Allenby Capital Limited (Nominated Adviser 
  and Joint Broker) 
  David Worlidge / Asha Chotai                 [phone] 
 Peterhouse Corporate Finance Ltd (Joint 
  Broker) 
  Lucy Williams / Duncan Vasey                 [phone] 
 Instinctif Partners                           [phone] 
  Melanie Toyne Sewell / Rozi Morris            [e-mail] 
 

Notes to editors

About Feedback plc

Feedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and improved workflows for practitioners involved in medical research and treating patients. TexRAD(R) , the Company's patented quantitative image texture analysis technology, has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 50 of the world's leading research institutions across Europe, North America, Asia and Australasia. The Cadran platform provides a suite of medical imaging tools for decision support. The Cadran range includes the picture archiving communication system (PACS) to provide decision support for scan analysis, diagnostic workstations which provide secure remote access to view scans on demand, and products to securely share and transport patient data.

For more information visit www.fbk.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOARLMLTMBIBBJP

(END) Dow Jones Newswires

July 20, 2018 02:00 ET (06:00 GMT)